Published in J Biol Chem on January 28, 2002
ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature (2012) 2.53
Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke (2012) 2.18
Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J (2004) 1.98
Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol (2008) 1.95
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest (2006) 1.92
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol (2006) 1.91
Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res (2009) 1.71
Angiotensin 1-7 reduces mortality and rupture of intracranial aneurysms in mice. Hypertension (2014) 1.54
Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension (2009) 1.52
ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol (2010) 1.51
Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension (2009) 1.45
Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol (2006) 1.44
Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol (2008) 1.42
Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension (2009) 1.41
Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats. PLoS One (2015) 1.39
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol (2010) 1.34
Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension (2009) 1.32
The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag (2008) 1.30
New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension (2009) 1.28
ACE2 gene expression is up-regulated in the human failing heart. BMC Med (2004) 1.28
The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol (2008) 1.26
Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol (2008) 1.24
Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut (2005) 1.23
Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne) (2014) 1.22
ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol (2008) 1.20
MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol (2008) 1.20
Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol (2008) 1.20
ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol (2013) 1.19
Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays. Am J Physiol Regul Integr Comp Physiol (2011) 1.18
Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes (2012) 1.17
ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One (2011) 1.16
Oxidative stress and metabolic pathologies: from an adipocentric point of view. Oxid Med Cell Longev (2014) 1.16
Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem (2008) 1.11
Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol (2010) 1.11
Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol (2013) 1.10
Recent advances involving the renin-angiotensin system. Exp Cell Res (2012) 1.09
Identification of intracellular proteins and signaling pathways in human endothelial cells regulated by angiotensin-(1-7). J Proteomics (2015) 1.09
Genetic variants associated with development of TMD and its intermediate phenotypes: the genetic architecture of TMD in the OPPERA prospective cohort study. J Pain (2013) 1.08
Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol (2011) 1.08
Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int (2013) 1.07
Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension (2013) 1.07
Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol (2009) 1.06
Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med (2010) 1.05
Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc (2013) 1.05
Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab (2012) 1.04
ACE2 activation promotes antithrombotic activity. Mol Med (2010) 1.04
Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail (2009) 1.04
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One (2013) 1.03
Identification of new participants in the rainbow trout (Oncorhynchus mykiss) oocyte maturation and ovulation processes using cDNA microarrays. Reprod Biol Endocrinol (2006) 1.02
Nonclassical renin-angiotensin system and renal function. Compr Physiol (2012) 1.02
Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol (2007) 1.02
Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. Am J Physiol Renal Physiol (2012) 1.01
New angiotensins. J Mol Med (Berl) (2008) 1.00
Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent. Biol Sex Differ (2010) 1.00
Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells. Anal Biochem (2007) 1.00
Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol (2008) 1.00
Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol (2013) 0.99
Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension (2013) 0.98
Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol (2011) 0.97
Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol (2010) 0.96
Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. Drug Discov Today (2010) 0.96
Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens (2010) 0.95
Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest (2013) 0.95
Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem (2003) 0.94
New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens (2012) 0.93
Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept (2012) 0.93
Classical Renin-Angiotensin system in kidney physiology. Compr Physiol (2014) 0.92
Genetic variants in the apelin system and blood pressure responses to dietary sodium interventions: a family-based association study. J Hypertens (2010) 0.92
Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther (2010) 0.92
Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol (2011) 0.91
Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol (2012) 0.91
Association of genetic variants in the apelin-APJ system and ACE2 with blood pressure responses to potassium supplementation: the GenSalt study. Am J Hypertens (2010) 0.91
Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry. Anal Biochem (2009) 0.91
Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci (2015) 0.91
Angiotensin-converting enzyme 2: the first decade. Int J Hypertens (2011) 0.90
The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol (2011) 0.89
ACE2, angiotensin-(1–7), and Mas: the other side of the coin. Pflugers Arch (2013) 0.89
Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure. Hypertension (2011) 0.89
Angiotensin peptides and lung cancer. Curr Cancer Drug Targets (2011) 0.89
Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res (2009) 0.88
Systemic and uteroplacental renin--angiotensin system in normal and pre-eclamptic pregnancies. Ther Adv Cardiovasc Dis (2008) 0.87
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair (2011) 0.87
Angiotensin-converting enzyme 2: central regulator for cardiovascular function. Curr Hypertens Rep (2010) 0.87
Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice. Am J Physiol Renal Physiol (2013) 0.87
Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System. Int J Hypertens (2012) 0.86
Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas. J Physiol (2013) 0.86
Apelin and pulmonary hypertension. Pulm Circ (2011) 0.86
Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. PLoS One (2012) 0.85
Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens (2012) 0.85
Effects of ACE2 inhibition in the post-myocardial infarction heart. J Card Fail (2010) 0.85
From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol (2014) 0.85
Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev (2012) 0.85
Angiotensin II relaxations of bovine adrenal cortical arteries: role of angiotensin II metabolites and endothelial nitric oxide. Hypertension (2008) 0.84
New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One (2014) 0.84
Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats. PLoS One (2014) 0.84
Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. Exp Physiol (2009) 0.84
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 32.01
A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med (2002) 6.37
The effects of postmastectomy adjuvant radiotherapy on immediate two-stage prosthetic breast reconstruction: a systematic review. Plast Reconstr Surg (2013) 2.74
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res (2010) 2.27
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27
Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol (2003) 1.81
Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. Mol Microbiol (2006) 1.79
ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem (2004) 1.60
Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses. J Immunol (2007) 1.52
Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos (2005) 1.34
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res (2011) 1.32
Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res (2010) 1.31
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood (2013) 1.20
Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol (2011) 1.20
Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc (2002) 1.18
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem J (2010) 1.18
Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci (2005) 1.09
A randomized comparative trial between Acticoat and SD-Ag in the treatment of residual burn wounds, including safety analysis. Burns (2006) 1.08
Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. J Clin Microbiol (2008) 1.06
Hybridization assay of hepatitis B virus by QCM peptide nucleic acid biosensor. Biosens Bioelectron (2007) 1.01
Epidemiological and genetic diversity of Staphylococcus aureus causing bloodstream infection in Shanghai, 2009-2011. PLoS One (2013) 0.99
Optimization of polysaccharides from Panax japonicus C.A. Meyer by RSM and its anti-oxidant activity. Int J Biol Macromol (2011) 0.98
Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant (2005) 0.98
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol (2011) 0.97
Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant (2007) 0.97
Mass spectrometric techniques for label-free high-throughput screening in drug discovery. Anal Chem (2007) 0.95
Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. APMIS (2010) 0.94
Polysaccharides from Panax japonicus C.A. Meyer and their antioxidant activities. Carbohydr Polym (2013) 0.92
Use of structure-based drug design approaches to obtain novel anthranilic acid acyl carrier protein synthase inhibitors. J Med Chem (2005) 0.92
A fluorescence-based coupling reaction for monitoring the activity of recombinant human NAD synthetase. Assay Drug Dev Technol (2005) 0.92
Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4. Bioorg Med Chem Lett (2006) 0.91
Direct identification and quantification of aspartyl succinimide in an IgG2 mAb by RapiGest assisted digestion. Anal Chem (2009) 0.91
Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis (2007) 0.90
Quantitative susceptibility mapping of small objects using volume constraints. Magn Reson Med (2012) 0.90
Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8). J Med Chem (2006) 0.87
A simple and efficient method for deriving neurospheres from bone marrow stromal cells. Biochem Biophys Res Commun (2008) 0.87
Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome. J Am Chem Soc (2014) 0.86
FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging (2014) 0.86
SAM: String-based sequence search algorithm for mitochondrial DNA database queries. Forensic Sci Int Genet (2010) 0.86
Molecular characterization of Staphylococcus aureus from surgical site infections in orthopedic patients in an orthopedic trauma clinical medical center in Shanghai. Surg Infect (Larchmt) (2015) 0.86
Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays. Assay Drug Dev Technol (2010) 0.84
Efficacy of ultrasound in the treatment of osteoarthritis of the knee. Orthop Surg (2011) 0.84
Characterization of eptifibatide during drug formulation stability assays. J Pharm Biomed Anal (2003) 0.83
VR PTSD exposure therapy results with active duty OIF/OEF combatants. Stud Health Technol Inform (2009) 0.83
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor. J Med Chem (2010) 0.82
An intelligent virtual human system for providing healthcare information and support. Stud Health Technol Inform (2011) 0.82
Primary Cutaneous Nocardiosis in a Patient With Nephrotic Syndrome: A Case Report and Review of the Literature. Medicine (Baltimore) (2016) 0.82
High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases. J Biomol Screen (2011) 0.81
N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride nanoparticle as a novel delivery system for parathyroid hormone-related protein 1-34. Int J Pharm (2010) 0.81
miRNA-101 Suppresses Epithelial-to-Mesenchymal Transition by Targeting HMGA2 in Pancreatic Cancer Cells. Anticancer Agents Med Chem (2016) 0.81
Virtual Iraq: initial results from a VR exposure therapy application for combat-related PTSD. Stud Health Technol Inform (2008) 0.80
The effect of microgravity on tissue structure and function of rat testis. Braz J Med Biol Res (2011) 0.79
The preliminary outcome of syndactyly management in children with a new external separation device. J Pediatr Orthop B (2015) 0.79
Fluid resuscitation for major burn patients with the TMMU protocol. Burns (2009) 0.79
Knockdown of Mad2 induces osteosarcoma cell apoptosis-involved Rad21 cleavage. J Orthop Sci (2011) 0.79
Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorg Med Chem Lett (2010) 0.79
STRIVE: Stress Resilience In Virtual Environments: a pre-deployment VR system for training emotional coping skills and assessing chronic and acute stress responses. Stud Health Technol Inform (2012) 0.79
Experimental demonstration of real-time adaptively modulated DDO-OFDM systems with a high spectral efficiency up to 5.76bit/s/Hz transmission over SMF links. Opt Express (2014) 0.78
Microenvironmental regulation of inducible nitric oxide synthase expression and nitric oxide production in mouse bone marrow-derived mast cells. J Leukoc Biol (2012) 0.78
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. J Med Chem (2005) 0.78
Improved MR venography using quantitative susceptibility-weighted imaging. J Magn Reson Imaging (2013) 0.78
The effect of immediate surgical bipolar plasmakinetic transurethral resection of the prostate on prostatic hyperplasia with acute urinary retention. Asian J Androl (2015) 0.77
Configuration of a scintillation proximity assay for the activity assessment of recombinant human adenine phosphoribosyltransferase. Assay Drug Dev Technol (2006) 0.77
Neonatal ventral hippocampal lesion as a valid model of schizophrenia: evidence from sensory gating study. Chin Med J (Engl) (2012) 0.77
Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents. J Pharmacol Exp Ther (2011) 0.77
[Analysis and identification of Poria cocos peels harvested from different producing areas by FTIR and 2D-IR correlation spectroscopy]. Guang Pu Xue Yu Guang Pu Fen Xi (2014) 0.77
Previous multiple abdominal surgeries: a valid contraindication to abdominal free flap breast reconstruction? Eplasty (2012) 0.77
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res Ther (2014) 0.77
Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant (2007) 0.77
Development of a high-throughput assay for two inositol-specific phospholipase Cs using a scintillation proximity format. Assay Drug Dev Technol (2003) 0.76
Advances in multimodality imaging through a hybrid PET/MRI system. Crit Rev Biomed Eng (2009) 0.76
VR enhanced upper extremity motor training for post-stroke rehabilitation: task design, clinical experiment and visualization on performance and progress. Stud Health Technol Inform (2007) 0.76
Development of a homogeneous AlphaLISA ubiquitination assay using ubiquitin binding matrices as universal components for the detection of ubiquitinated proteins. Biochim Biophys Acta (2012) 0.76
Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. J Med Chem (2011) 0.76
Multibranched triarylamine end-capped triazines with aggregation-induced emission and large two-photon absorption cross-sections. Chem Commun (Camb) (2010) 0.76
A survey of injuries and medical conditions affecting competitive adult outrigger canoe paddlers on O'ahu. Hawaii Med J (2009) 0.75
[Erectile dysfunction induced by pelvic fracture urethral injury]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2004) 0.75
[Multi-center clinical study of acticoat (nanocrystalline silver dressing) for the management of residual burn wounds]. Zhonghua Shao Shang Za Zhi (2006) 0.75
[Analysis of spectral features based on water content of desert vegetation]. Guang Pu Xue Yu Guang Pu Fen Xi (2010) 0.75
[Experimental study on cryopreservation of immature dendritic cells derived from cord blood]. Zhonghua Shao Shang Za Zhi (2006) 0.75
Femoral head epiphysis growth and development among Chinese children aged 0-5 years. Eur J Pediatr (2008) 0.75
The impact of hepatitis C status on postoperative outcome. Anesth Analg (2003) 0.75
[Electromyographic study of congenital clubfoot]. Zhongguo Dang Dai Er Ke Za Zhi (2008) 0.75
Visual Tracking via Dynamic Graph Learning. IEEE Trans Pattern Anal Mach Intell (2018) 0.75
Caught on camera. Nurs Stand (2008) 0.75
Identifying and managing frailty in Brazil: a scoping review protocol. JBI Evid Synth (2020) 0.75
Previously unrecognized trends in diabetes consumption clusters in medicare. Am J Manag Care (2013) 0.75
A homogeneous scintillation proximity format for monitoring the activity of recombinant human long-chain-fatty-acyl-CoA synthetase 5. Assay Drug Dev Technol (2004) 0.75
[An experimental study on the role of indirect antigen presentation pathway on the immunogenetic of epidermal cells]. Zhonghua Shao Shang Za Zhi (2003) 0.75
Antibacterial effect of dressings containing multivalent silver ion carried by zirconium phosphate on experimental rat burn wounds. Wound Repair Regen (2009) 0.75
Characterization of the kinase domain of the ephrin-B3 receptor tyrosine kinase using a scintillation proximity assay. Assay Drug Dev Technol (2003) 0.75
[A proteomic study of peripheral blood mononuclear cells in patients undergoing cardiopulmonary bypass]. Zhejiang Da Xue Xue Bao Yi Xue Ban (2010) 0.75
Orthodontics in a quantum world I: the rationale for a new approach. Int J Orthod Milwaukee (2008) 0.75
The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma. Cell Physiol Biochem (2017) 0.75